Breast cancer liquid biopsy is a process of detecting tumor cells in a liquid blood sample. It is an alternative to surgical biopsy procedures that enables doctors and surgeons to diagnose and treat breast cancer. It is also use to collect tumor information from blood samples.
The breast cancer liquid biopsy market size in 2021 was $ 124.46 million, and by 2030 it will reach $604.71 million with a CAGR of 19.2% 2021-2030.
The World Cancer Research Fund International stated that, in 2020, there were more than 2.26 million new breast cancer cases in women. Factors such as early menarche before age 12, late natural menopause after age 55, and first pregnancy over 30 are similar with the increased risk of breast cancer in women.
Growth drivers of breast cancer liquid biopsy market
Factors contributing to the market‘s growth are increasing incidence of breast cancer, use of liquid biopsy instruments, technological innovations in breast cancer, increasing preference for noninvasive procedures, and rising patient awareness towards minimally invasive breast cancer liquid biopsy procedures. As per research by Centres for Disease Control and Prevention, by 2050, female breast cancer is predict to witness an increase in cases by 52%. According to a report by GLOBOCAN, out of all deaths caused due to cancer, breast cancer accounted for 7% of deaths in 2020.
Other factors, such as the growing funding for R&D in breast liquid biopsy, initiatives taken by government and health organizations, and a rise in breast cancer liquid biopsy
reagent approvals are contributing to the market’s growth.
Lack of accessibility, awareness regarding breast cancer in underdeveloped countries, lack of skilled professionals is the factors hampering the growth.
Growing preference for noninvasive procedures to provide lucrative growth opportunity
During the forecast period, the primary factors propelling the growth of the breast cancer liquid biopsy market are the general trend toward people’s preferences for various noninvasive healthcare services, whether treatments or diagnoses. The adoption and availability of personalized medicine have also never been easier thanks to the development of liquid biopsy, and the growing trend of developing customized treatments will support the market’s overall growth throughout the forecast period.
- On the basis of indicators, the industry is segment into Circulating Tumour Cells, Circulating Cell-free DNA, and Extracellular Vesicles.
The Circulating Cell-free DNA (cfDNA) Segment is expected to account for a major portion of the market. Circulating tumor cells and cell-free DNA have been recognized as potential blood-based biomarkers that can provide prognostic and predictive information. The ability to detect emerging genomic alterations linked to drug resistance, the capacity to clarify cancer prognosis and diagnose cancer recurrence or progression, and the potential to monitor tumor molecular profiling in real-time at multiple time points are the factors attributed to the growth of this segment.
- Based on end-user, the breast cancer liquid biopsy market is segment into hospitals, physician laboratories, reference laboratories, research institutes.
On the basis of end-user, the largest global market is the Reference Laboratories segment.
Reference Laboratories are the leading segment because they charge low, and they can perform high-volume routine and specialty testing.
North America is expecting to have a considerable market share.
Reasons for the rising incidence of breast cancer in this region, growing value for noninvasive therapy, and better health infrastructure.
According to the National Breast Cancer Foundation, 62% of breast cancer cases in 2019 were recognize at a localized stage. In the United States, female breast cancer accounted for approximately 15.2% of all new cancer cases.
- Johnson & Johnson
- Epic Sciences
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories